Table 2.
Multivariate analyses
| Outcomes | Hazard ratio (95% CI) |
P |
|---|---|---|
| Grade II to IV acute GVHD | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 2.90 (2.25-3.74) | <.0001 |
| 6-8/8 HLA-matched UCB | 1.80 (1.35-2.39) | <.0001 |
| Grade III to IV acute GVHD | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 4.95 (3.09-7.93) | <.0001 |
| 6-8/8 HLA-matched UCB | 2.74 (1.59-4.72) | .0003 |
| Chronic GVHD | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 1.28 (0.95-1.73) | .10 |
| 6-8/8 HLA-matched UCB | 1.18 (0.84-1.67) | .34 |
| Nonrelapse mortality | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 3.05 (2.00-4.67) | <.0001 |
| 6-8/8 HLA-matched UCB | 2.28 (1.35-3.86) | .002 |
| Age, y | ||
| ≤16 | 1.00 | |
| >16 | 2.98 (1.79-4.96) | <.0001 |
| Relapse | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 0.65 (0.45-0.91) | .026 |
| 6-8/8 HLA-matched UCB | 0.95 (0.66-1.36) | .79 |
| Disease status at transplantation | ||
| 1st CR | 1.00 | |
| 2nd CR | 1.63 (1.22-2.18) | .001 |
| Overall survival | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 1.38 (1.02-1.87) | .037 |
| 6-8/8 HLA-matched UCB | 1.34 (0.94-1.92) | .10 |
| Age, y | ||
| ≤16 | 1.00 | |
| >16 | 1.50 (1.09-2.07) | .014 |
| Disease status at transplantation | ||
| 1st CR | 1.00 | |
| 2nd CR | 1.45 (1.12-1.89) | .005 |
| HCT comorbidity score | ||
| ≤2 | 1.00 | |
| ≥3 | 1.36 (1.04-1.79) | .030 |
| Leukemia-free survival | ||
| Donor type | ||
| Haplo-HSCT | 1.00 | |
| ≤5/8 HLA-matched UCB | 1.17 (0.89-1.53) | .26 |
| 6-8/8 HLA-matched UCB | 1.17 (0.87-1.58) | .28 |
| Disease status at transplantation | ||
| 1st CR | 1.00 | |
| 2nd CR | 1.42 (1.13-1.79) | .003 |
| HCT comorbidity score | ||
| ≤2 | 1.00 | |
| ≥3 | 1.39 (1.09-1.77) | .007 |